Knee Osteoarthritis
Conditions
Brief summary
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy
Interventions
DRUGMesenchymal Stem Cells
Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use
Sodium Hyaluronate administrated for intra-articular use
Sponsors
Wuxi Cellular Biopharmaceutical Group Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects who understand and voluntarily sign the consent form before this study； 2. According to the diagnostic criteria (American Rheumatology Association, clinical + radiology criteria), patients with knee osteoarthritis are definitely diagnosed；Course of knee osteoarthritis was more than 6 months; 3. Age: 40-75, males and females； 4. The subjects' WOMAC score was 24-72 5. The Kellgren Lawrence grade (X-ray axial position of knee joint) of subjects was grade II / III; 6. Subjects are generally in good condition and can walk autonomously, except for those who use wheelchairs, walking aids or crutches.
Exclusion criteria
1. The subject may be allergic to the main cell preparation components (B vitamins, amino acids and so on). 2. The subject received systemic and / or local treatment with autologous and / or allogeneic mesenchymal progenitor cells. 3. The subject considered obese. 4. Laboratory test (any item meets): neutrophil absolute number \< 1.0 × 10\^9 / L, platelet count \< 50 × 10\^9 / L, serum albumin \< 30g / L, serum creatinine \> upper limit of 1.2 times normal value range, total bilirubin、alanine aminotransferase、aspartate aminotransferase \> upper limit of 2 times of normal value range. 5. The subject has diseases or symptoms may affect VAS, WOMAC and so on. 6. The subject has serious and poorly controlled concomitant diseases, such as (but not limited to) nervous system, cardiovascular, liver, kidney, gastrointestinal and endocrine diseases, which may prevent the subjects from participating in the study according to the judgment of the researchers. 7. The subject has an history malignant tumour. 8. The subject has connective tissue disease or rheumatoid arthritis、chondropathy、Chondrocalcinosis articularis、 Hemochromatosis、inflammatory arthropathy、avascular necrosis of femoral head、Paget's disease、hemophilic arthropathy、infectional arthritis、Charcot' s disease、villonodular synovitis or synovial chondromatosis. 9. The subject has severe generalized infectious diseases or local knee infection (including skin and intra-articular infection) in the 3 months prior to this trial. 10. According to the researchers, the subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on. 11. The subject had any other coagulation dysfunction caused by acute or chronic diseases, according to the judgment of the researchers, this coagulation dysfunction may endanger the safety of patients and / or affect the judgment of knee joint evaluation indicators. 12. The subject has received arthroscopic surgery or other open surgery related to knee joint operation in the 6 months prior to this trial. 13. The subject has received other intra-articular injections, including but not limited to hyaluronic acid, hormone, PRP, BMP (bone morphogenetic protein) , hypertonic glucose and so on for KOA in the 3 months preceding the trial. 14. The subject has received aminoglucose or chondroitin sulfate within 1 month before the treatment. 15. The subject has used dexamethasone, prednisone, hydrocortisone and other hormones orally / intravenously within 1 month before the treatment. 16. The subject has attenuated or live attenuated vaccine injection with 1 month before the treatment. 17. The subject has undergone knee prosthesis or a plan of knee prosthesis within the trial. 18. The subject has contraindication of MRI, included but not only: the subject installed heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip after aneurysm surgery, drug infusion device implanted in vivo, any electronic device implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil, strainer, ECG monitor, metal suture, shrapnel or sand of body, plate fixation and steel nail after fracture surgery, artificial cochlea, middle ear shift plant, metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill patient and so on. 19. The subject tests positive for: HIV, HBV, HCV and treponema pallidum. 20. The subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial. 21. The subject has participated in any other clinical trial in the 3 months prior to this trial. 22. The subject (including male subjects) has fertility, sperm donation or egg donation plans during the trial period; the female subject is pregnant, lactating or having a positive pregnancy test. 23. The subject is legally disabled by reference to the law of the people's Republic of China on the protection of disabled persons (April 2008). 24. The subject has any other unsuitable condition (such as factors reducing the follow-up compliance) to be determined by the investigator. 25. The Kellgren Lawrence grade (X-ray axial position of knee joint) of any knee joint of the subjects was grade IV.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| WOMAC score | 48 weeks | The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points；96 points mean a worse outcome,will be tested at 48 weeks after the first injection |
| MRI quantitative analysis of articular cartilage | 24 weeks | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MRI quantitative analysis of articular cartilage (volume change) | 12、24、 48 and 104 weeks | Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 12、24、 48 and 104 weeks after the first injection |
| VAS Score | 4、12、24、36、48、60、72、84、104 weeks | Visual Analogue Scale/Score；0-10 points；10 points mean the worse outcome,will be tested at 4、12、24、36、48、60、72、84 and 104 weeks after the first injection |
| SF-36 | 4、12、24、36、48、60、72、84、104 weeks | The Medical Outcomes Study 36-Item Short-Form Health Survey;0-100 points；100 points mean a better outcome, will be tested at 4、12、24、36、48、60、72、84 and 104 weeks after the first injection |
| WOMAC Score | 4、12、24、36、60、72、84 and 104 weeks | The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points；96 points mean a worse outcome, will be tested at 4、12、24、36、60、72、84 and 104 weeks after the first injection |
| mJSW | 104 weeks | Minimum joint space width (mJSW) of the knee, will be measured at baseline and 104 weeks |
| Physical examination | Day 0、week 1、2、3、4、12、24、36、48、60、72、84、104 weeks | Height and weight will be tested and combined to report BMI in kg/m\^2at Day 0 and week 1、2、3、4、12、24、36、48、60、72、84、104 weeks |
| Adverse Events and Serious Adverse Events | Day 0 to 104 weeks | AE and SAE, will be assessed within the 104 week time span |
| Whole-Organ Magnetic Resonance Imaging Score | 12、24、48 and 104 weeks | Whole-Organ Magnetic Resonance Imaging Score(WORMS) of the knee; 0-332points; 332 points means the worst outcome; will be assessed at 12、24、48 and104 weeks |
| MRI quantitative analysis of articular cartilage （volume change percentage） | 12、48、104 weeks | Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 12、48、104 weeks after the first injection |
Countries
China
Outcome results
None listed